Abstract:Abstract New SARS-CoV-2 variants continue to emerge from the current global pandemic, some of which can replicate faster and with greater transmissibility and pathogenicity. In particular, UK501Y.V1 identified in UK, SA501Y.V2 in South Africa, and BR501Y.V3 in Brazil are raising serious concerns as they spread quickly and contain spike protein mutations that may facilitate escape from current antibody therapies and vaccine protection. Here, we constructed a panel of 28 SARS-CoV-2 pseudoviruses bearing single or combined mutations found in the spike protein of these three variants, as well as additional nine mutations that within or close by the major antigenic sites in the spike protein identified in the GISAID database. These pseudoviruses were tested against a panel of monoclonal antibodies (mAbs), including some approved for emergency use to treat SARS-CoV-2 infection, and convalescent patient plasma collected early in the pandemic. SA501Y.V2 pseudovirus was the most resistant, in magnitude and breadth, against mAbs and convalescent plasma, followed by BR501Y.V3, and then UK501Y.V1. This resistance hierarchy corresponds with Y144del and 242-244del mutations in the N-terminal domain as well as K417N/T, E484K and N501Y mutations in the receptor binding domain (RBD). Crystal structural analysis of RBD carrying triple K417N-E484K-N501Y mutations found in SA501Y.V2 bound with mAb P2C-1F11 revealed a molecular basis for antibody neutralization and escape. SA501Y.V2 and BR501Y.V3 also acquired substantial ability to use mouse and mink ACE2 for entry. Taken together, our results clearly demonstrate major antigenic shifts and potentially broadening the host range of SA501Y.V2 and BR501Y.V3, which pose serious challenges to our current antibody therapies and vaccine protection.

SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usage

Spike mutations in SARS-CoV-2 variants confer resistance to antibody neutralization

Analysis of SARS-CoV-2 Variant Mutations Reveals Neutralization Escape Mechanisms and the Ability to Use ACE2 Receptors from Additional Species.

The Challenge of Emerging SARS-CoV-2 Mutants to Vaccine Development

Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization

No Higher Infectivity but Immune Escape of SARS-CoV-2 501Y.V2 Variants

Multiple SARS-CoV-2 Variants Exhibit Variable Target Cell Infectivity and Ability to Evade Antibody Neutralization

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization.

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape

SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2

Effect of SARS-CoV-2 spike mutations on animal ACE2 usage and in vitro neutralization sensitivity

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Antibody evasion by the P.1 strain of SARS-CoV-2

Characterization of SARS-CoV-2 Variants B.1.617.1 (kappa), B.1.617.2 (delta) and B.1.618 on Cell Entry, Host Range, and Sensitivity to Convalescent Plasma and ACE2 Decoy Receptor

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

Structural Basis for Continued Antibody Evasion by the SARS-CoV-2 Receptor Binding Domain

Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies

Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity

Key Mutations on Spike Protein Altering ACE2 Receptor Utilization and Potentially Expanding Host Range of Emerging SARS-CoV-2 Variants